HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262
Amyotrophic Lateral Sclerosis
About this trial
This is an interventional treatment trial for Amyotrophic Lateral Sclerosis focused on measuring ALS, Placebo-Controlled, Double-Blind, Regimen Specific Appendix, Lou Gehrig's Disease, ABBV-CLS-7262, Calico Life Sciences
Eligibility Criteria
Inclusion Criteria: No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683). Exclusion Criteria: The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683). Based on the metabolism of the compound, the concomitant use of certain inhibitors and inducers of cytochrome P450 enzymes. Any clinically significant ECG abnormalities. Clinically significant clinical laboratory abnormalities.
Sites / Locations
- Healey Center for ALS at Mass General
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
ABBV-CLS-7262 Dose 1
ABBV-CLS-7262 Dose 2
Matching Placebo